360 related articles for article (PubMed ID: 32993545)
1. Metabolic characterization of aggressive breast cancer cells exhibiting invasive phenotype: impact of non-cytotoxic doses of 2-DG on diminishing invasiveness.
Fujita M; Imadome K; Somasundaram V; Kawanishi M; Karasawa K; Wink DA
BMC Cancer; 2020 Sep; 20(1):929. PubMed ID: 32993545
[TBL] [Abstract][Full Text] [Related]
2. Leukemia cells demonstrate a different metabolic perturbation provoked by 2-deoxyglucose.
Miwa H; Shikami M; Goto M; Mizuno S; Takahashi M; Tsunekawa-Imai N; Ishikawa T; Mizutani M; Horio T; Gotou M; Yamamoto H; Wakabayashi M; Watarai M; Hanamura I; Imamura A; Mihara H; Nitta M
Oncol Rep; 2013 May; 29(5):2053-7. PubMed ID: 23440281
[TBL] [Abstract][Full Text] [Related]
3. Targeting aspartate aminotransferase in breast cancer.
Thornburg JM; Nelson KK; Clem BF; Lane AN; Arumugam S; Simmons A; Eaton JW; Telang S; Chesney J
Breast Cancer Res; 2008; 10(5):R84. PubMed ID: 18922152
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity of high dose ascorbic acid is enhanced by 2-deoxy-d-glucose in glycolytic melanoma cells.
Hill-Mündel K; Nohr D
Biochem Biophys Res Commun; 2021 Mar; 546():90-96. PubMed ID: 33578294
[TBL] [Abstract][Full Text] [Related]
5. Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells.
Berthe A; Zaffino M; Muller C; Foulquier F; Houdou M; Schulz C; Bost F; De Fay E; Mazerbourg S; Flament S
Breast Cancer Res Treat; 2018 Oct; 171(3):581-591. PubMed ID: 29971627
[TBL] [Abstract][Full Text] [Related]
6. Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines.
Millon SR; Ostrander JH; Brown JQ; Raheja A; Seewaldt VL; Ramanujam N
Breast Cancer Res Treat; 2011 Feb; 126(1):55-62. PubMed ID: 20390344
[TBL] [Abstract][Full Text] [Related]
7. Mass spectrometry analysis shows the biosynthetic pathways supported by pyruvate carboxylase in highly invasive breast cancer cells.
Phannasil P; Ansari IH; El Azzouny M; Longacre MJ; Rattanapornsompong K; Burant CF; MacDonald MJ; Jitrapakdee S
Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):537-551. PubMed ID: 27890529
[TBL] [Abstract][Full Text] [Related]
8. Metabolic plasticity of metastatic breast cancer cells: adaptation to changes in the microenvironment.
Simões RV; Serganova IS; Kruchevsky N; Leftin A; Shestov AA; Thaler HT; Sukenick G; Locasale JW; Blasberg RG; Koutcher JA; Ackerstaff E
Neoplasia; 2015 Aug; 17(8):671-84. PubMed ID: 26408259
[TBL] [Abstract][Full Text] [Related]
9. 2-NBDG fluorescence imaging of hypermetabolic circulating tumor cells in mouse xenograft model of breast cancer.
Cai H; Peng F
J Fluoresc; 2013 Jan; 23(1):213-20. PubMed ID: 23054302
[TBL] [Abstract][Full Text] [Related]
10. Optical Imaging of Glucose Uptake and Mitochondrial Membrane Potential to Characterize Her2 Breast Tumor Metabolic Phenotypes.
Madonna MC; Fox DB; Crouch BT; Lee J; Zhu C; Martinez AF; Alvarez JV; Ramanujam N
Mol Cancer Res; 2019 Jul; 17(7):1545-1555. PubMed ID: 30902832
[TBL] [Abstract][Full Text] [Related]
11. [Uptake of 2-NBDG by human breast cancer cells in vitro].
Hu H; Shan XH; Zhu W; Qian H; Xu WR; Wang YF
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):507-10. PubMed ID: 21029693
[TBL] [Abstract][Full Text] [Related]
12. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.
Robertson FM; Simeone AM; Mazumdar A; Shah AH; McMurray JS; Ghosh S; Cristofanilli M
J Exp Ther Oncol; 2008; 7(4):299-312. PubMed ID: 19227010
[TBL] [Abstract][Full Text] [Related]
13. Molecular heterogeneity in breast carcinoma cells with increased invasive capacities.
Negro G; Aschenbrenner B; Brezar SK; Cemazar M; Coer A; Gasljevic G; Savic D; Sorokin M; Buzdin A; Callari M; Kvitsaridze I; Jewett A; Vasileva-Slaveva M; Ganswindt U; Skvortsova I; Skvortsov S
Radiol Oncol; 2020 Feb; 54(1):103-118. PubMed ID: 32061169
[TBL] [Abstract][Full Text] [Related]
14. Role of nitric oxide in pancreatic cancer cells exhibiting the invasive phenotype.
Fujita M; Somasundaram V; Basudhar D; Cheng RYS; Ridnour LA; Higuchi H; Imadome K; No JH; Bharadwaj G; Wink DA
Redox Biol; 2019 Apr; 22():101158. PubMed ID: 30852389
[TBL] [Abstract][Full Text] [Related]
15. Glycolytic inhibitor 2-Deoxy-d-Glucose activates migration and invasion in glioblastoma cells through modulation of the miR-7-5p/TFF3 signaling pathway.
Shukla A; Gupta P; Singh R; Mishra DP
Biochem Biophys Res Commun; 2018 May; 499(4):829-835. PubMed ID: 29621542
[TBL] [Abstract][Full Text] [Related]
16. Clotrimazole preferentially inhibits human breast cancer cell proliferation, viability and glycolysis.
Furtado CM; Marcondes MC; Sola-Penna M; de Souza ML; Zancan P
PLoS One; 2012; 7(2):e30462. PubMed ID: 22347377
[TBL] [Abstract][Full Text] [Related]
17. Caffeic Acid Targets AMPK Signaling and Regulates Tricarboxylic Acid Cycle Anaplerosis while Metformin Downregulates HIF-1α-Induced Glycolytic Enzymes in Human Cervical Squamous Cell Carcinoma Lines.
Tyszka-Czochara M; Bukowska-Strakova K; Kocemba-Pilarczyk KA; Majka M
Nutrients; 2018 Jun; 10(7):. PubMed ID: 29958416
[TBL] [Abstract][Full Text] [Related]
18. 2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype.
O'Neill S; Porter RK; McNamee N; Martinez VG; O'Driscoll L
Sci Rep; 2019 Mar; 9(1):3788. PubMed ID: 30846710
[TBL] [Abstract][Full Text] [Related]
19. Triple Negative Breast Cancer and Breast Epithelial Cells Differentially Reprogram Glucose and Lipid Metabolism upon Treatment with Triterpenic Acids.
Guerra ÂR; Paulino AF; Castro MM; Oliveira H; Duarte MF; Duarte IF
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32784479
[TBL] [Abstract][Full Text] [Related]
20. Metabolic characterization of invaded cells of the pancreatic cancer cell line, PANC-1.
Fujita M; Imadome K; Imai T
Cancer Sci; 2017 May; 108(5):961-971. PubMed ID: 28256041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
